51
Participants
Start Date
February 12, 2019
Primary Completion Date
January 17, 2020
Study Completion Date
July 22, 2020
BI 655130
Solution for infusion
Placebo
Solution for infusion
Finlay Medical Research Corp, Miami
University of South Florida, Tampa
ForCare Clinical Research, Inc., Tampa
Clinical Physiology Associates, Fort Myers
The Indiana Clinical Trials Center, PC, Plainfield
Unity Clinical Research, Oklahoma City
Dermatology Treatment and Research Center, PA, Dallas
Center for Clinical Studies, Webster
Progressive Clinical Research, San Antonio
Center for Dermatology and Plastic Surgery, Scottsdale
University of Alberta Hospital (University of Alberta), Edmonton
NewLab Clinical Research Inc., St. John's
Innovaderm Research Inc., Montreal
Aichi Medical University Hospital, Aichi, Nagakute
National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka
Kurume University Hospital, Fukuoka, Kurume
Hosui General Medical Clinic, Hokkaido, Sapporo
Tennocho Ekimae Dermatology and Allergology, Kanagawa, Yokohama
University Hospital Kyoto Prefectural University of Medicine, Kyoto, Kyoto
Nagasaki University Hospital, Nagasaki, Nagasaki
Osaka City University Hospital, Osaka, Osaka
Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji
Showa University Hospital, Tokyo, Shinagawa-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY